受药物安全问题报道冲击，Morphosys(MOR.US)称诺华制药(NVS.US)收购仍将按计划进行

智通财经04-29

智通财经APP获悉，周一，德国生物技术公司Morphosys(MOR.US)股价下滑，受到一则关于其药物或具有安全风险的新闻报道影响，但Morphosys表示，诺华制药(NVS.US)对其收购仍有望在今年上半年完成。在Morphosys发表声明之前，专业网站STATNews援引两位知情人士消息报道称，该公司正在开发的一种用于治疗骨髓纤维化(一种影响骨髓的罕见血癌)的实验性药物pelabresib...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2431594928?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-29 20:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2431594928","market":"hk","top_or_hot":-1,"title":"受药物安全问题报道冲击，Morphosys(MOR.US)称诺华制药(NVS.US)收购仍将按计划进行","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，周一，德国生物技术公司Morphosys(MOR.US)股价下滑，受到一则关于其药物或具有安全风险的新闻报道影响，但Morphosys表示，诺华制药(NVS.US)对其收购仍有望在今年上半年完成。在Morphosys发表声明之前，专业网站STATNews援引两位知情人士消息报道称，该公司正在开发的一种用于治疗骨髓纤维化(一种影响骨髓的罕见血癌)的实验性药物pelabresib...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1114925.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>受药物安全问题报道冲击，Morphosys(MOR.US)称诺华制药(NVS.US)收购仍将按计划进行</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n受药物安全问题报道冲击，Morphosys(MOR.US)称诺华制药(NVS.US)收购仍将按计划进行\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-29 20:21 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1114925.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，周一，德国生物技术公司Morphosys(MOR.US)股价下滑，受到一则关于其药物或具有安全风险的新闻报道影响，但Morphosys表示，诺华制药(NVS.US)对其收购仍有望在今年上半年完成。在Morphosys发表声明之前，专业网站STATNews援引两位知情人士消息报道称，该公司正在开发的一种用于治疗骨髓纤维化(一种影响骨髓的罕见血癌)的实验性药物pelabresib...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1114925.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1114925.html","article_id":"2431594928","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2431594928","pubTimestamp":1714393287,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，周一，德国生物技术公司Morphosys股价下滑，受到一则关于其药物或具有安全风险的新闻报道影响，但Morphosys表示，诺华制药对其收购仍有望在今年上半年完成。Pelabresib被视为Morphosys公司最有前途的药物之一，也是诺华制药对该公司感兴趣的原因之一。Morphosys发言人补充道：“诺华的收购计划正在稳步推进。”诺华制药于今年2月达成协议，将以27亿欧元的价格收购Morphosys公司。截至发稿，Morphosys美股盘前下跌2.38%，诺华制药美股盘前上涨了0.63%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4588":"碎股","BK4578":"CAR-T","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","01477":"欧康维视生物-B","BK1191":"制药","NVS":"诺华","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","MOR":"Morphosys AG","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4139":"生物科技","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4007":"制药"},"translate_title":"Shocked by reports of drug safety issues, Morphosys (MOR.US) says Novartis (NVS.US) acquisition will still proceed as planned","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":1,"MOR":1,"01477":1},"content_text":"智通财经APP获悉，周一，德国生物技术公司Morphosys(MOR.US)股价下滑，受到一则关于其药物或具有安全风险的新闻报道影响，但Morphosys表示，诺华制药(NVS.US)对其收购仍有望在今年上半年完成。在Morphosys发表声明之前，专业网站STATNews援引两位知情人士消息报道称，该公司正在开发的一种用于治疗骨髓纤维化(一种影响骨髓的罕见血癌)的实验性药物pelabresib存在安全问题。Pelabresib被视为Morphosys公司最有前途的药物之一，也是诺华制药对该公司感兴趣的原因之一。“我们一般不公开讨论与监管机构的互动。我们对pelabresib和ruxolitinib联合疗法的效益及风险情况仍充满信心。”Morphosys公司发言人在给路透社的电子邮件回复中说。Morphosys发言人补充道：“诺华的收购计划正在稳步推进。”诺华制药于今年2月达成协议，将以27亿欧元(28.9亿美元)的价格收购Morphosys公司。诺华制药拒绝对STATNews的报道发表评论。截至发稿，Morphosys美股盘前下跌2.38%，诺华制药美股盘前上涨了0.63%。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2431594928"}